



## **Test Update 876**

**Posted Date** 05/08/2024

**Effective Date** 06/04/2024

**Update Type** [Test Discontinued](#)

**CPT Code** 81170, G0452-26

### **BCR/ABL1 Kinase Domain Mutation**

Order Code: KMBCR

Fee Code: NA053/NA054 (CPT 81170, G0452-26)

The MLabs Molecular Diagnostics Laboratory will discontinue offering their BCR/ABL1 Kinase Domain Mutation assay effective June 4, 2024. Requests for this test will be sent to ARUP Laboratories test ID 2008420.

This test is indicated for patients who have an established diagnosis of BCR::ABL1-positive leukemia to identify mutations associated with resistance to tyrosine kinase inhibitor (TKI) therapy. This test is performed using Sanger Sequencing and evaluated codons 235-368. The ARUP assay BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance by Next-Generation Sequencing (test ID 2008420) covers more of the ABL1 gene (codons 46-542; including regions with less common resistance mutations) and is expected to have a lower limit of detection for mutations owing to the NGS methodology. This test is recommended as a substitute for patients who have an established diagnosis of BCR::ABL1-positive leukemia to identify TKI resistance mutations. BCR/ABL1 Analysis, Quantitative (order code QBCR) remains the appropriate test for diagnosis and monitoring of BCR::ABL1-positive leukemias. Propriate test for diagnosis and monitoring of BCR::ABL1-positive leukemias.

[View PDF](#)